MedicaidPrior AuthMedium impact
Prior Authorization Required for Onasemnogene Abeparvovec-brve (Itvisma) Effective September 1, 2026
Texas Medicaid·TX · Neurology, Pediatrics, Genetics·Prior Authorization
Effective date
Sep 1, 2026
We identified it
Aug 5, 2026
Summary
Effective September 1, 2026, prior authorization is now required for onasemnogene abeparvovec-brve (Itvisma), a gene therapy for spinal muscular atrophy, using HCPCS code J3405. The treatment is limited to one lifetime administration and is not covered for patients with tracheostomy or invasive ventilator support. Providers must submit detailed clinical documentation including confirmed SMN1 gene mutation, baseline AAV9 antibody titers, normal lab values, and contraception counseling before treatment.
Action Required
By August 31, 2026: Billing team must update authorization workflow to require prior authorization for HCPCS code J3405 (onasemnogene abeparvovec-brve). Configure billing system to flag J3405 claims as requiring Special Medical Prior Authorization (SMPA) form submission. Providers must document all required criteria including: (1) patient age ≥2 years, (2) confirmed SMA diagnosis with SMN1 gene mutation documentation, (3) baseline AAV9 antibody titer ≤1:50, (4) normal CBC/liver function/creatinine labs, (5) no active infection, (6) contraception counseling for reproductive-age patients, (7) no prior SMA gene therapy or confirmation of clinical deterioration/discontinuation if previously on nusinersen or risdiplam. Flag exclusions: patients with tracheostomy or invasive ventilator support are not eligible. Front desk staff must screen for these contraindications at scheduling. Billing team must implement lifetime limit tracking for code J3405 per patient. Claims submitted without prior authorization or missing required documentation will be denied. Update provider education materials with new authorization requirements and submission deadline.